Week in Review: CITIC Offers $3.6 Billion to Acquire China Biologic

Deals and Financings

Trials and Approvals

• CStone Pharma of Suzhou dosed the first patient in an Australian Phase I trial of CS3006, a MEK inhibitor;
• Yantai's Luye Pharma said the CFDA accepted its IND filing for a China Class 1.1 novel analgesia candidate;

Company News

• CASI Pharma reached an agreement with Shijiazhuang Yiling Pharma to manufacture two generic drugs, entecavir and cilostazol, for China use;
• Tot Biopharm, a Suzhou oncology company, completed a monoclonal antibodies (mAb) manufacturing facility, for itself and other pharmas on a CDMO basis;
  

Industry Insights

• Dr. Jonathan Wang, Senior Managing Director of OrbiMed Asia, told ChinaBio® Today that China's biopharma sector is "a once-in-a-lifetime opportunity," though probably a bubble at the moment, which Dr. Wang sees as ending in a correction, not a crash, because the fundamentals of China's underlying market and support system remain strong.
  

Stock Symbols: (NSDQ: CBPO) (ASX: CSL; USOTC: CSLLY) (NSDQ: PCRX) (HK: 2269) (HK: 2186) (NSDQ: CASI)

Share this with colleagues:

Original Article: Week in Review: CITIC Offers $3.6 Billion to Acquire China Biologic

More From BioPortfolio on "Week in Review: CITIC Offers $3.6 Billion to Acquire China Biologic"